Tirilazad
Appearance
From Wikipedia, the free encyclopedia
Chemical compound
Pharmaceutical compound
| Clinical data | |
|---|---|
| Other names | (8S,10S,13S,14S,16R,17S)-17-[2-[4-(2,6-dipyrrolidin-1-ylpyrimidin-4-yl)piperazin-1-yl]acetyl]-10,13,16-trimethyl-6,7,8,12,14,15,16,17-octahydrocyclopenta[a]phenanthren-3-one |
| ATC code | |
| Identifiers | |
| |
| CAS Number |
|
| PubChem CID | |
| ChemSpider |
|
| UNII | |
| KEGG |
|
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C38H52N6O2 |
| Molar mass | 624.874 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| ☒NcheckY (what is this?) (verify) | |
Tirilazad is a drug that has been proposed to treat acute ischaemic stroke. When tested on animal models, tirilazad protects brain tissue, and reduces brain damage. However, the drug fails to treat, and even worsens a stroke when studied on a human being.[1]
References
[edit ]- ^ Bath PM, Iddenden R, Bath FJ, Orgogozo JM, et al. (Tirilazad International Steering Committee) (2001). "Tirilazad for acute ischaemic stroke". The Cochrane Database of Systematic Reviews (4) CD002087. doi:10.1002/14651858.CD002087. PMID 11687138.
Stub icon
This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.